{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:25:17Z","timestamp":1759623917772,"version":"build-2065373602"},"reference-count":32,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,9,30]]},"DOI":"10.1248\/bpb.b25-00417","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T22:09:32Z","timestamp":1759183772000},"page":"1456-1463","source":"Crossref","is-referenced-by-count":0,"title":["Effect of 2-Hydroxypropyl-&lt;i&gt;\u03b3&lt;\/i&gt;-cyclodextrin on Renal Inflammation in Alport Mouse Model"],"prefix":"10.1248","volume":"48","author":[{"given":"Jun","family":"Horizono","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keito","family":"Mizumoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann","family":"Suico","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"},{"name":"Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aina","family":"Shirakawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Kaseda","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"},{"name":"Wellcome Centre for Cell-Matrix Research, University of Manchester, Manchester M13 9PT, U.K"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Sannomiya","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Tsuhako","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimi","family":"Owaki","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Shiraga","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riko","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kumabe","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Shuto","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"},{"name":"Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Kai","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"},{"name":"Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 862\u20130973, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"doi-asserted-by":"crossref","unstructured":"1) Cosgrove D, Liu S. Collagen IV diseases: a focus on the glomerular basement membrane in Alport syndrome. <i>Matrix Biol.<\/i>, <b>57-58<\/b>, 45\u201354 (2017).","key":"1","DOI":"10.1016\/j.matbio.2016.08.005"},{"doi-asserted-by":"crossref","unstructured":"2) Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and type IV collagen. <i>N. Engl. J. Med.<\/i>, <b>348<\/b>, 2543\u20132556 (2003).","key":"2","DOI":"10.1056\/NEJMra022296"},{"doi-asserted-by":"crossref","unstructured":"3) Gross O, Licht C, Anders HJ, <i>et al<\/i>. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. <i>Kidney Int.<\/i>, <b>81<\/b>, 494\u2013501 (2012).","key":"3","DOI":"10.1038\/ki.2011.407"},{"doi-asserted-by":"crossref","unstructured":"4) Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of cyclodextrins and drug\/cyclodextrin complexes. <i>Molecules<\/i>, <b>23<\/b>, 1161 (2018).","key":"4","DOI":"10.3390\/molecules23051161"},{"doi-asserted-by":"crossref","unstructured":"5) Mitrofanova A, Molina J, Varona Santos J, <i>et al<\/i>. Hydroxypropyl-\u03b2-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. <i>Kidney Int.<\/i>, <b>94<\/b>, 1151\u20131159 (2018).","key":"5","DOI":"10.1016\/j.kint.2018.06.031"},{"doi-asserted-by":"crossref","unstructured":"6) Wang Z, Jiang T, Li J, Proctor G, Mcmanaman JL, Lucia S, Chua S, Levi M. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVB db\/db mice with type 2 diabetes. <i>Diabetes<\/i>, <b>54<\/b>, 2328\u20132335 (2005).","key":"6","DOI":"10.2337\/diabetes.54.8.2328"},{"doi-asserted-by":"crossref","unstructured":"7) Ji W, Zhang Y, Shao W, Kankala RK, Chen A. <i>\u03b2<\/i>-Cyclodextrin-based nanoassemblies for the treatment of atherosclerosis. <i>Regen. Biomater.<\/i>, <b>11<\/b>, rbae071 (2024).","key":"7","DOI":"10.1093\/rb\/rbae071"},{"doi-asserted-by":"crossref","unstructured":"8) Zimmer S, Grebe A, Bakke SS, <i>et al<\/i>. Cyclodextrin promotes atherosclerosis regression <i>via<\/i> macrophage reprogramming. <i>Sci. Transl. Med.<\/i>, <b>8<\/b>, 333ra50 (2016).","key":"8","DOI":"10.1126\/scitranslmed.aad6100"},{"doi-asserted-by":"crossref","unstructured":"9) Scantlebery AML, Ochodnicky P, Kors L, Rampanelli E, Butter LM, El Boumashouli C, Claessen N, Teske GJ, van den Bergh Weerman MA, Leemans JC, Roelofs JJTH, Florquin S. <i>\u03b2<\/i>-Cyclodextrin counteracts obesity in Western diet-fed mice but elicits a nephrotoxic effect. <i>Sci. Rep.<\/i>, <b>9<\/b>, 17633 (2019).","key":"9","DOI":"10.1038\/s41598-019-53890-z"},{"doi-asserted-by":"crossref","unstructured":"10) Yamada Y, Ishitsuka Y, Kondo Y, <i>et al<\/i>. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C. <i>Br. J. Pharmacol.<\/i>, <b>178<\/b>, 2727\u20132746 (2021).","key":"10","DOI":"10.1111\/bph.15464"},{"doi-asserted-by":"crossref","unstructured":"11) Hastings C, Liu B, Hurst B, Cox GF, Hrynkow S. Intravenous 2-hydroxypropyl-<i>\u03b2<\/i>-cyclodextrin (Trappsol\u00ae CycloTM) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: results of a phase 1 trial. <i>Mol. Genet. Metab.<\/i>, <b>137<\/b>, 309\u2013319 (2022).","key":"11","DOI":"10.1016\/j.ymgme.2022.10.004"},{"doi-asserted-by":"crossref","unstructured":"12) Soga M, Ishitsuka Y, Hamasaki M, Yoneda K, Furuya H, Matsuo M, Ihn H, Fusaki N, Nakamura K, Nakagata N, Endo F, Irie T, Era T. HPGCD outperforms HPBCD as a potential treatment for niemann-pick disease type C during disease modeling with iPS cells. <i>Stem Cells<\/i>, <b>33<\/b>, 1075\u20131088 (2015).","key":"12","DOI":"10.1002\/stem.1917"},{"doi-asserted-by":"crossref","unstructured":"13) Tanaka Y, Yamada Y, Ishitsuka Y, Matsuo M, Shiraishi K, Wada K, Uchio Y, Kondo Y, Takeo T, Nakagata N, Higashi T, Motoyama K, Arima H, Mochinaga S, Higaki K, Ohno K, Irie T. Efficacy of 2-hydroxypropyl-<i>\u03b2<\/i>-cyclodextrin in Niemann-Pick disease type C model mice and its pharmacokinetic analysis in a patient with the disease. <i>Biol. Pharm. Bull.<\/i>, <b>38<\/b>, 844\u2013851 (2015).","key":"13","DOI":"10.1248\/bpb.b14-00726"},{"doi-asserted-by":"crossref","unstructured":"14) Rheault MN, Kren SM, Thielen BK, Mesa HA, Crosson JT, Thomas W, Sado Y, Kashtan CE, Segal Y. Mouse model of X-linked Alport syndrome. <i>J. Am. Soc. Nephrol.<\/i>, <b>15<\/b>, 1466\u20131474 (2004).","key":"14","DOI":"10.1097\/01.ASN.0000130562.90255.8F"},{"doi-asserted-by":"crossref","unstructured":"15) Kaseda S, Horizono J, Sannomiya Y, <i>et al<\/i>. Efficacy of Nrf2 activation in a proteinuric Alport syndrome mouse model. <i>Life Sci. Alliance<\/i>, <b>8<\/b>, e202503330 (2025).","key":"15","DOI":"10.26508\/lsa.202503330"},{"doi-asserted-by":"crossref","unstructured":"16) Kaseda S, Sannomiya Y, Horizono J, Kuwazuru J, Suico MA, Ogi S, Sasaki R, Sunamoto H, Fukiya H, Nishiyama H, Kamura M, Niinou S, Koyama Y, Nara F, Shuto T, Onuma K, Kai H. Novel Keap1-Nrf2 protein-protein interaction inhibitor UBE-1099 ameliorates progressive phenotype in Alport syndrome mouse model. <i>Kidney360<\/i>, <b>3<\/b>, 687\u2013699 (2022).","key":"16","DOI":"10.34067\/KID.0004572021"},{"doi-asserted-by":"crossref","unstructured":"17) Omachi K, Kaseda S, Yokota T, Kamura M, Teramoto K, Kuwazuru J, Kojima H, Nohara H, Koyama K, Ohtsuki S, Misumi S, Takeo T, Nakagata N, Li JD, Shuto T, Suico MA, Miner JH, Kai H. Metformin ameliorates the severity of experimental Alport syndrome. <i>Sci. Rep.<\/i>, <b>11<\/b>, 7053 (2021).","key":"17","DOI":"10.1038\/s41598-021-86109-1"},{"doi-asserted-by":"crossref","unstructured":"18) Sannomiya Y, Kaseda S, Kamura M, Yamamoto H, Yamada H, Inamoto M, Kuwazuru J, Niino S, Shuto T, Suico MA, Kai H. The role of discoidin domain receptor 2 in the renal dysfunction of alport syndrome mouse model. <i>Ren. Fail.<\/i>, <b>43<\/b>, 510\u2013519 (2021).","key":"18","DOI":"10.1080\/0886022X.2021.1896548"},{"doi-asserted-by":"crossref","unstructured":"19) Yokota T, Omachi K, Suico MA, Kamura M, Kojima H, Fukuda R, Motomura K, Teramoto K, Kaseda S, Kuwazuru J, Takeo T, Nakagata N, Shuto T, Kai H. STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model. <i>Nephrol. Dial. Transplant.<\/i>, <b>33<\/b>, 214\u2013223 (2018).","key":"19","DOI":"10.1093\/ndt\/gfx246"},{"doi-asserted-by":"crossref","unstructured":"20) Yokota T, Omachi K, Suico MA, Kojima H, Kamura M, Teramoto K, Kaseda S, Kuwazuru J, Shuto T, Kai H. Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome. <i>PLOS ONE<\/i>, <b>12<\/b>, e0183959 (2017).","key":"20","DOI":"10.1371\/journal.pone.0183959"},{"doi-asserted-by":"crossref","unstructured":"21) Fukuda R, Suico MA, Kai Y, Omachi K, Motomura K, Koga T, Komohara Y, Koyama K, Yokota T, Taura M, Shuto T, Kai H. Podocyte p53 limits the severity of experimental Alport syndrome. <i>J. Am. Soc. Nephrol.<\/i>, <b>27<\/b>, 144\u2013157 (2016).","key":"21","DOI":"10.1681\/ASN.2014111109"},{"doi-asserted-by":"crossref","unstructured":"22) Koga T, Kai Y, Fukuda R, Morino-Koga S, Suico MA, Koyama K, Sato T, Shuto T, Kai H. Mild electrical stimulation and heat shock ameliorates progressive proteinuria and renal inflammation in mouse model of Alport syndrome. <i>PLOS ONE<\/i>, <b>7<\/b>, e43852 (2012).","key":"22","DOI":"10.1371\/journal.pone.0043852"},{"doi-asserted-by":"crossref","unstructured":"23) Yamada Y, Ishitsuka Y, Fukaura-Nishizawa M, <i>et al<\/i>. Intracerebroventricular 2-hydroxypropyl-\u03b3-cyclodextrin alleviates hepatic manifestations without distributing to the liver in a murine model of Niemann-Pick disease type C. <i>Life Sci.<\/i>, <b>350<\/b>, 122776 (2024).","key":"23","DOI":"10.1016\/j.lfs.2024.122776"},{"doi-asserted-by":"crossref","unstructured":"24) Liu B, Ramirez CM, Miller AM, Repa JJ, Turley SD, Dietschy JM. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. <i>J. Lipid Res.<\/i>, <b>51<\/b>, 933\u2013944 (2010).","key":"24","DOI":"10.1194\/jlr.M000257"},{"doi-asserted-by":"crossref","unstructured":"25) Wang Y, Gao H, Huang X, Chen Z, Kang P, Zhou Y, Qin D, Zhang W, Liu J. Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis. <i>Carbohydr. Polym.<\/i>, <b>292<\/b>, 119632 (2022).","key":"25","DOI":"10.1016\/j.carbpol.2022.119632"},{"doi-asserted-by":"crossref","unstructured":"26) Brettner FEB, Gier S, Haessler A, Schreiner J, Vogel-Kindgen S, Windbergs M. Anti-inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and reduce inflammation. <i>Discov. Nano<\/i>, <b>19<\/b>, 211 (2024).","key":"26","DOI":"10.1186\/s11671-024-04175-6"},{"doi-asserted-by":"crossref","unstructured":"27) Kritharides L, Kus M, Brown AJ, Jessup W, Dean RT. Hydroxypropyl-\u03b2-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells. <i>J. Biol. Chem.<\/i>, <b>271<\/b>, 27450\u201327455 (1996).","key":"27","DOI":"10.1074\/jbc.271.44.27450"},{"doi-asserted-by":"crossref","unstructured":"28) van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJL, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. <i>J. Pathol.<\/i>, <b>212<\/b>, 209\u2013217 (2007).","key":"28","DOI":"10.1002\/path.2175"},{"doi-asserted-by":"crossref","unstructured":"29) Mori Y, Ajay AK, Chang JH, Mou S, Zhao H, Kishi S, Li J, Brooks CR, Xiao S, Woo HM, Sabbisetti VS, Palmer SC, Galichon P, Li L, Henderson JM, Kuchroo VK, Hawkins J, Ichimura T, Bonventre JV. KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. <i>Cell Metab.<\/i>, <b>33<\/b>, 1042\u20131061.e7 (2021).","key":"29","DOI":"10.1016\/j.cmet.2021.04.004"},{"doi-asserted-by":"crossref","unstructured":"30) Tanaka Y, Ishitsuka Y, Yamada Y, Kondo Y, Takeo T, Nakagata N, Higashi T, Motoyama K, Arima H, Matsuo M, Higaki K, Ohno K, Irie T. Influence of Npc1 genotype on the toxicity of hydroxypropyl-<i>\u03b2<\/i>- cyclodextrin, a potentially therapeutic agent, in Niemann-Pick type C disease models. <i>Mol. Genet. Metab. Rep.<\/i>, <b>1<\/b>, 19\u201330 (2014).","key":"30","DOI":"10.1016\/j.ymgmr.2013.12.003"},{"doi-asserted-by":"crossref","unstructured":"31) Youssef EM, Wu GY. Subnormal serum liver enzyme levels: a review of pathophysiology and clinical significance. <i>J. Clin. Transl. Hepatol.<\/i>, <b>12<\/b>, 428\u2013435 (2024).","key":"31","DOI":"10.14218\/JCTH.2023.00446"},{"doi-asserted-by":"crossref","unstructured":"32) Merrill AH Jr, Henderson JM. Diseases associated with defects in vitamin B6 metabolism or utilization. <i>Annu. Rev. Nutr.<\/i>, <b>7<\/b>, 137\u2013156 (1987).","key":"32","DOI":"10.1146\/annurev.nu.07.070187.001033"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00417\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:42:59Z","timestamp":1759549379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00417\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00417","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"b25-00417"}}